Quantcast

Comments about ‘Top court hearing Utah firm's case as groups fight Myriad Genetics' gene patenting’

Return to article »

Published: Sunday, April 14 2013 11:09 p.m. MDT

Comments
  • Oldest first
  • Newest first
  • Most recommended
CPelkey
Laramie, WY

I don't mean to be picky, but this story - and a host of others around the country this day - make the same oversight. The sentence that starts with "Women with BRCA mutations...."

As a male breast cancer patient, I am particularly bothered by that omission. Obviously, breast cancer is a major concern among women, but men, too, can suffer from the BRCA1 and BRCA2 mutations and it increases the risk of male breast cancer from 0.05% to 7%. Breast Cancer in men can be even more dangerous, largely because symptoms are often ignored., too, can suffer from the BRCA1 and BRCA2 mutations and it increases the risk of male breast cancer from 0.05% to 7%. Breast Cancer in men can be even more dangerous, largely because symptoms are often ignored.

It's a small omission, but it could contribute to a fatal mistake.

casual observer
Salt Lake City, UT

The ACLU and others want all the benefits of very expensive genetic research, but they don't want to encourage it by offering patent protection to those who invest $100s of millions in it. Hopefully the SCOTUS knows that you can't have it both ways.

to comment

DeseretNews.com encourages a civil dialogue among its readers. We welcome your thoughtful comments.
About comments